Loading...

FBIO - Fortress Biotech, Inc.

Analyst Coverage Resumed Signal for 03-15-2024
Analyst Coverage Resumed: FBIO rating Buy by ROTH MKM
Price Target: $10


Loading Chart FBIO

Stock Signal Information


Signal

Analyst Coverage Resumed: FBIO rating Buy by ROTH MKM
Price Target: $10
Report Date: 03-15-2024
Symbol: FBIO - Fortress Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Coverage Resumed: FBIO rating Buy by ROTH MKM
Price Target: $10

  FBIO Technical Analysis

Company Contact

Fortress Biotech, Inc. (FBIO)
2 Gansevoort St Fl 9
New York City, NEW YORK 10014
Phone: 17816524500
Website: http://www.fortressbiotech.com
CEO: Dr. Lindsay Rosenwald

FBIO, Fortress Biotech, Inc.

FBIO Fortress Biotech, Inc. Logo Image

NASDAQ, Nasdaq Capital Market


Company Profile

Fortress Biotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel pharmaceutical and biotechnology products. The company is headquartered in New York City, New York and currently employs 88 full-time employees. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.